Novo Nordisk, Europe's largest company, has reassured stakeholders regarding potential business impacts from US tariff threats under President Trump. Despite existing tariffs on imports from various countries, the company reported a remarkable 86% increase in sales of its weight-loss drug, Wegovy, and an overall revenue growth of 26% to 290bn kroner. While Novo anticipates slower sales growth between 16% and 24% this year, its CEO remains optimistic about navigating challenges. Despite some disappointments in trial results for another obesity drug, CagriSema, the company is moving forward with regulatory submissions early next year.
Novo Nordisk reported sales of its weight-loss drug, Wegovy, jumped by 86% last year, leading to a total sales growth of 26% to a higher-than-forecast 290bn kroner (32bn).
In response to concerns over potential tariffs imposed by Donald Trump, Novo Nordisk's CEO expressed confidence in the company's business position and its ability to meet the demands of the new US administration.
Collection
[
|
...
]